EvlaBio

KHAN Technology Transfer Fund focuses on early-stage life sciences investments, particularly first-in-class therapies for indications with a high unmet medical need. Its pipeline is sourced primarily from research institutes such as those belonging to the Max Planck Society, with which it has a preferred partnership and a co-investment agreement worth €18 million. KHAN also has access to the drug discovery incubator Lead Discovery Center, established by the tech transfer office Max Planck Innovation.